This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Fluciclatide
- DrugBank Accession Number
- DB14842
- Background
Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis. The conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Fluciclatide (DB14842)
- Weight
- Average: 1816.02
Monoisotopic: 1814.7325222 - Chemical Formula
- C75H115FN18O27S3
- Synonyms
- Not Available
- External IDs
- AH-111585
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UQ6CV583Q3
- CAS number
- 879894-00-5
- InChI Key
- VXFFXZSNVKXXIB-XVUFQIMXSA-N
- InChI
- InChI=1S/C75H115FN18O27S3/c76-52-13-11-51(12-14-52)39-87-121-45-65(100)83-19-23-113-27-31-117-34-36-118-35-33-116-30-26-112-22-18-82-64(99)44-120-43-62(97)80-15-5-4-9-54-70(106)93-58-47-123-124-48-59(94-72(108)56(38-67(102)103)89-61(96)40-86-68(104)53(90-73(58)109)10-6-16-85-75(78)79)74(110)91-55(37-50-7-2-1-3-8-50)71(107)92-57(46-122-49-66(101)88-54)69(105)84-20-24-114-28-32-115-29-25-111-21-17-81-63(98)42-119-41-60(77)95/h1-3,7-8,11-14,39,53-59H,4-6,9-10,15-38,40-49H2,(H2,77,95)(H,80,97)(H,81,98)(H,82,99)(H,83,100)(H,84,105)(H,86,104)(H,88,101)(H,89,96)(H,90,109)(H,91,110)(H,92,107)(H,93,106)(H,94,108)(H,102,103)(H4,78,79,85)/b87-39+/t53-,54-,55-,56?,57-,58-,59-/m0/s1
- IUPAC Name
- 2-[(1R,4S,10R,13S,16R,19S,25S)-13-benzyl-25-(3-carbamimidamidopropyl)-10-({2-[2-(2-{2-[2-(carbamoylmethoxy)acetamido]ethoxy}ethoxy)ethoxy]ethyl}carbamoyl)-4-{4-[2-({[17-(2-{[(E)-[(4-fluorophenyl)methylidene]amino]oxy}acetamido)-3,6,9,12,15-pentaoxaheptadecan-1-yl]carbamoyl}methoxy)acetamido]butyl}-3,6,12,15,18,21,24,27-octaoxo-8,29,30-trithia-2,5,11,14,17,20,23,26-octaazabicyclo[14.11.4]hentriacontan-19-yl]acetic acid
- SMILES
- NC(=O)COCC(=O)NCCOCCOCCOCCNC(=O)[C@@H]1CSCC(=O)N[C@@H](CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO\N=C\C2=CC=C(F)C=C2)C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N1
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Diagnostic Breast Cancer / Head And Neck Cancer / High Grade Glioma (HGG) / Lung Cancer / Renal Cell Carcinoma (RCC) / Sarcomas / Solid Tumors 1 somestatus stop reason just information to hide 2 Completed Diagnostic Head And Neck Cancer / High Grade Glioma (HGG) / Lung Cancer / Melanoma / Sarcomas 1 somestatus stop reason just information to hide 2 Terminated Diagnostic Renal Cell Carcinoma (RCC) 1 somestatus stop reason just information to hide 2 Terminated Diagnostic Renal Neoplasms 1 somestatus stop reason just information to hide 2 Withdrawn Diagnostic Monoclonal Gammopathy of Undetermined Significance (MGUS) / Multiple Myeloma (MM) / Smoldering Multiple Myeloma (SMM) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0858 mg/mL ALOGPS logP -0.25 ALOGPS logP -11 Chemaxon logS -4.3 ALOGPS pKa (Strongest Acidic) 3.51 Chemaxon pKa (Strongest Basic) 11.87 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 31 Chemaxon Hydrogen Donor Count 18 Chemaxon Polar Surface Area 634.48 Å2 Chemaxon Rotatable Bond Count 56 Chemaxon Refractivity 455.28 m3·mol-1 Chemaxon Polarizability 188.7 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:30 / Updated at September 18, 2024 01:28